Ophthalmic follow-up of patients with tyrosinaemia type I on NTBC.
Research output: Contribution to journal › Article
Colleges, School and Institutes
NTBC has revolutionized the management of tyrosinaemia type I, although animal experiments have shown that long-term administration may produce corneal opacities analogous to those in tyrosinaemia type II. We have assessed the prevalence of ocular side-effects in 11 tyrosinaemia type I patients on NTBC attending the Birmingham Children's Hospital. Despite high plasma tyrosine concentrations in some patients, they did not experience symptoms or signs of ocular toxicity.
|Number of pages||4|
|Journal||Journal of Inherited Metabolic Disease|
|Publication status||Published - 1 Jan 2003|